MEK inhibitors under development for treatment of non-small-cell lung cancer.

about

MEK inhibitors under development for treatment of non-small-cell lung cancer.

Item

http://www.wikidata.org/entity/Q47318847

description

2017 nî lūn-bûn

@nan

2017年の論文

@ja

2017年学术文章

@wuu

2017年学术文章

@zh

2017年学术文章

@zh-cn

2017年学术文章

@zh-hans

2017年学术文章

@zh-my

2017年学术文章

@zh-sg

2017年學術文章

@yue

2017年學術文章

@zh-hant

name

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@en

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@nl

type

Item

label

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@en

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@nl

prefLabel

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@en

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@nl

P1476

MEK inhibitors under development for treatment of non-small-cell lung cancer.

@en

P2093

Chul Kim

http://www.w3.org/2001/XMLSchema#string

Giuseppe Giaccone

http://www.w3.org/2001/XMLSchema#string

P2860

Synthetic lethal interaction of combined BCL-XL and MEK inhibition promotes tumor regressions in KRAS mutant cancer models

Improved survival with vemurafenib in melanoma with BRAF V600E mutation

Use of mitogenic cascade blockers for treatment of C-Raf induced lung adenoma in vivo: CI-1040 strongly reduces growth and improves lung structure

ALK inhibitors in non-small cell lung cancer: the latest evidence and developments

RDEA119/BAY 869766: a potent, selective, allosteric inhibitor of MEK1/2 for the treatment of cancer

Discovery of TAK-733, a potent and selective MEK allosteric site inhibitor for the treatment of cancer

Design and synthesis of novel allosteric MEK inhibitor CH4987655 as an orally available anticancer agent

K-Ras(G12C) inhibitors allosterically control GTP affinity and effector interactions

Mechanism of MEK inhibition determines efficacy in mutant KRAS- versus BRAF-driven cancers

Phase I pharmacokinetic and pharmacodynamic study of the oral, small-molecule mitogen-activated protein kinase kinase 1/2 inhibitor AZD6244 (ARRY-142886) in patients with advanced cancers

P304

17-30

http://www.w3.org/2001/XMLSchema#string

P31

scholarly article

review article

P356

10.1080/13543784.2018.1415324

http://www.w3.org/2001/XMLSchema#string

P407

English

P433

http://www.w3.org/2001/XMLSchema#string

P478

http://www.w3.org/2001/XMLSchema#string

P577

2017-12-07T00:00:00Z

http://www.w3.org/2001/XMLSchema#dateTime

P698

29216787

http://www.w3.org/2001/XMLSchema#string